Cardiovascular disease (CVD) is one of the most significant and costly public health
problems in the U.S. and worldwide. In addition to the well-established risk factors, such
as hypertension or diabetes, growing bodies of studies have demonstrated that vascular
calcification is another strong and independent predictor of cardiovascular morbidity and
mortality. The pathological process of vascular calcification includes many key
modulators of bone and mineral metabolism. Hence, the question is raised regarding
whether pharmacological agents for inhibiting bone loss can also provide a beneficial
impact on inhibiting vascular calcification to lower CVD risks.
The primary objectives of this study were to: 1) examine the association between
bisphosphonate use and the risk of a composite endpoint of congestive heart failure
(CHF), myocardial infarction (MI) or stroke hospitalization, and 2) examine the impact of
patient adherence to bisphosphonate therapy on the risk of CHF, MI or stroke hospitalization.
University of Minnesota PH.D. dissertation. April 2013. Major: Social, Administrative, and Clinical Pharmacy. Advisor: Dr. Wendy St. Peter. 1 computer file (PDF); xi, 126 pages, appendices 1-6.
The role of bisphosphonates: potential novel pharmaceutical therapy for reducing cardiovascular morbidity and mortality.
Retrieved from the University of Minnesota Digital Conservancy,
Content distributed via the University of Minnesota's Digital Conservancy may be subject to additional license and use restrictions applied by the depositor.